Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $295303.0.

  • Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) rose 1802.16% to $295303.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 1350.51%. This contributed to the annual value of $1.0 million for FY2024, which is 3.92% down from last year.
  • Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) amounted to $295303.0 in Q3 2025, which was up 1802.16% from $295303.0 recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) ranged from a high of $295303.0 in Q1 2025 and a low of $250211.0 during Q1 2024
  • In the last 4 years, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) had a median value of $250310.0 in 2023 and averaged $259291.7.
  • As far as peak fluctuations go, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) decreased by 3.92% in 2024, and later skyrocketed by 1802.16% in 2025.
  • Over the past 4 years, Coeptis Therapeutics Holdings' Depreciation & Amortization (CF) (Quarter) stood at $250346.0 in 2022, then fell by 0.01% to $250310.0 in 2023, then decreased by 0.04% to $250212.0 in 2024, then rose by 18.02% to $295303.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $295303.0 for Q3 2025, versus $295303.0 for Q2 2025 and $295303.0 for Q1 2025.